175 related articles for article (PubMed ID: 30909792)
1. Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma.
Cheng W; Kletas V; Kollmannsberger C; de Lemos M
J Oncol Pharm Pract; 2020 Jan; 26(1):67-73. PubMed ID: 30909792
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Suo A; Iqbal U; Lim J; Lee C; Gesy K; Iqbal N; Abbas T
Clin Genitourin Cancer; 2017 Jun; 15(3):e397-e404. PubMed ID: 28216279
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
Tan HS; Li H; Hong YW; Toh CK; Wong A; Lopes G; Tay MH; Chan A; Yao X; Tang T; Ng QS; Kanesvaran R; Chau NM; Tan MH
Clin Genitourin Cancer; 2015 Aug; 13(4):e285-e295. PubMed ID: 25541325
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
5. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G; Paillard MJ; Maurina T; Vernerey D; Nguyen Tan Hon T; Almotlak H; Stein U; Calcagno F; Berthod D; Robert E; Meurisse A; Thiery-Vuillemin A
Trials; 2018 Apr; 19(1):221. PubMed ID: 29650037
[TBL] [Abstract][Full Text] [Related]
6. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA; Heng DYC; Macfarlane RJ; Venner PM; Kapoor A; Hansen AR; Eigl BJ; Czaykowski P; Boyd B; Wang L; Basappa NS
Eur J Cancer; 2019 Feb; 108():69-77. PubMed ID: 30648632
[TBL] [Abstract][Full Text] [Related]
8. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsukav A
Med Oncol; 2018 Aug; 35(10):133. PubMed ID: 30128854
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
12. The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis.
Sun Y; Li J; Yang X; Zhang G; Fan X
Clin Genitourin Cancer; 2019 Oct; 17(5):e847-e859. PubMed ID: 31279483
[TBL] [Abstract][Full Text] [Related]
13. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
Ito T; Yamamoto K; Furukawa J; Harada K; Fujisawa M; Omura T; Yano I
J Clin Pharm Ther; 2022 Jan; 47(1):81-88. PubMed ID: 34669974
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis.
Abogunrin S; Ashaye AO; Cappelleri JC; Clair AG; Fahrbach K; Ramaswamy K; Serfass L; Srinivas S; Thomaidou D; Zanotti G
Future Oncol; 2019 Jun; 15(18):2175-2190. PubMed ID: 31010323
[TBL] [Abstract][Full Text] [Related]
15. [A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Cui C; Li S; Chi Z; Si L; Sheng X; Mao L; Lian B; Wang X; Tang B; Guo J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):375-8. PubMed ID: 26463030
[TBL] [Abstract][Full Text] [Related]
16. Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma.
Kawashima A; Uemura M; Kato T; Ujike T; Nagahara A; Fujita K; Imamura R; Yamanaka Y; Tomiyama E; Tanigawa G; Miyagawa Y; Yoshioka T; Miyake O; Nonomura N
Int J Clin Oncol; 2019 Jan; 24(1):78-86. PubMed ID: 30094693
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Jonasch E; Slack RS; Geynisman DM; Hasanov E; Milowsky MI; Rathmell WK; Stovall S; Juarez D; Gilchrist TR; Pruitt L; Ornstein MC; Plimack ER; Tannir NM; Rini BI
J Clin Oncol; 2018 Jun; 36(16):1588-1593. PubMed ID: 29641297
[TBL] [Abstract][Full Text] [Related]
18. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Buti S; Donini M; Bersanelli M; Gattara A; Leonardi F; Passalacqua R
Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
[TBL] [Abstract][Full Text] [Related]
19. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
